Connecting the dots...Provectus Biopharmaceuticals
May 15, 2012
PFE, JNJ
It is interesting to note that oncology contributed less than 2% of Pfizer's Q1 2012 revenues.
For JNJ, the figure is less than 4%.
No comments:
Post a Comment
Newer Post
Older Post
Home
No comments:
Post a Comment